Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05569759 · ClinicalTrials.gov registry record · Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
A Phase 2 study, sponsored by Kezar Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05569759 is a Phase 2 study that has completed, run by Kezar Life Sciences. The registered enrollment target is 24 participants.
The verdict
NCT05569759, a Phase 2 study, has completed, sponsored by Kezar Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
Interventions
- DRUG placebo
- DRUG zetomipzomib
- DRUG zetomipzomib in open-label extension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05569759
The ClinicalTrials.gov registry entry for NCT05569759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kezar Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT05569759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05569759 about?
NCT05569759 is a clinical study titled "A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)". This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 w...
What is the current status of trial NCT05569759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-05-23. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05569759?
The interventions under investigation include: placebo (DRUG), zetomipzomib (DRUG), zetomipzomib in open-label extension (DRUG).
Who is sponsoring clinical trial NCT05569759?
This trial is sponsored by Kezar Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.